Illumina, Inc. vs Tapestry, Inc. — how do they compare? Illumina, Inc. trades at $189.78 (market cap $27.94B), while Tapestry, Inc. trades at $141.81 (market cap $28.51B). The key difference: Illumina, Inc. and Tapestry, Inc. are close in size by market cap, and Tapestry, Inc. pays a 1.13% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TPR | |
|---|---|---|
Market Cap | $27.94B | $28.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $160.49 |
52-Week Low | $91.00 | $95.69 |
Enterprise Value | $29.33B | $31.37B |
Dividend Yield | — | 1.13% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TPR trades at $140.45, down 0.71% on the day, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 76.18% gross margin and 55.74% ROE, though net income margin fell to 8.44% in 2025. Recent quarters have consistently beaten EPS estimates, and analyst consensus is strongly bullish with a $183.88 price target. Cash flow trends are volatile, with 2025 showing a net outflow of $5.02B due to financing activities.
Outlook remains positive driven by earnings beats and digital growth, but high valuation ratios (P/E 43.13) and debt levels pose risks. The stock offers 31% upside to consensus target, supported by institutional buy ratings and strong brand momentum in luxury retail.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →